Nuvation Bio Inc. (NUVB) is a Healthcare stock trading at $5.54 (as of 2026-06-18), with a market capitalization of $1.66B and a trailing P/E of -11.1. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Nuvation Bio Inc. is a clinical-stage biopharmaceutical company developing therapeutic candidates in oncology, including small-molecule programs such as NUV-422 and other drug candidates targeting pathways involved in tumor growth and DNA damage response. It also develops a drug-drug conjugate platform using PARP inhibitor-based warheads for anti-cancer applications.